|1.||Patterson, Adam V: 2 articles (04/2013 - 10/2009)|
|2.||Syddall, Sophie P: 2 articles (04/2013 - 10/2009)|
|3.||Prosser, G A: 2 articles (10/2010 - 03/2010)|
|4.||Ackerley, D F: 2 articles (10/2010 - 03/2010)|
|5.||Patterson, A V: 2 articles (10/2010 - 03/2010)|
|6.||Tangney, Mark: 1 article (01/2015)|
|7.||Gelovani, Juri G: 1 article (01/2015)|
|8.||Lund, Kjetil B: 1 article (01/2015)|
|9.||McCormack, Emmet: 1 article (01/2015)|
|10.||Dubikovskaya, Elena A: 1 article (01/2015)|
10/01/2010 - "These findings may hold significance for identification and selection of nitroreductases for CB1954-mediated gene therapy, particularly when targeting tumors that are deficient in nucleotide excision repair. "
05/01/2008 - "Nitroreductases have raised a great interest due to their potential applications in bioremediation, biocatalysis, and biomedicine, especially in prodrug activation for chemotherapeutic cancer treatments. "
01/01/2015 - "Bacterial nitroreductases (NTRs) have been widely utilized in the development of novel antibiotics, degradation of pollutants, and gene-directed enzyme prodrug therapy (GDEPT) of cancer that reached clinical trials. "
10/01/2010 - "uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954."
03/01/2010 - "Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954."
01/01/1999 - "The hypoxia-dependent activation of nitroheterocyclic drugs by cellular nitroreductases leads to the formation of intracellular adducts between the drugs and cellular macromolecules. "
10/01/1995 - "Nitroimidazole markers of tumour hypoxia bind to normoxic liver and the question has been raised whether this is due to low oxygen concentration or microregional activity of specialised nitroreductases. "
10/01/1995 - "One of the most sensitive hypoxia detection methods is based on the observation that binding of nitroimidazoles to cellular macromolecules occurs as a result of hypoxia-dependent bioreduction by cellular nitroreductases. "
10/01/2009 - "Here, we describe a class of prodrugs, nitro-chloromethylindolines, which undergo hypoxia-selective activation by endogenous nitroreductases in tumor cells to form the corresponding amino compounds. "
07/01/2001 - "Firstly, oxygen deficiency in the core of solid tumors leads to enhanced activity of reducing enzymes, like for example nitroreductases, which can be used for site- specific conversion of prodrug to drug. "
|1.||Anti-Bacterial Agents (Antibiotics)
|5.||Hydroxylamine (Hydroxylamine Hydrochloride)